Transforming the global pig industry – The FDA has approved the PRP gene edit for use in the US food supply chain, which is a crucial step forward on the road to commercialisation. The PRP pig is resistant to the PRRS virus, which costs US producers alone US$1.2bn per annum.
In this podcast Charles Hall sits down with Jorgen Kokke, CEO of Genus PLC to discuss PRRS’s impact, the technology behind PRP, patent protection, next steps on commercialisation, and scaling up production.
